Etiology of angiogenesis inhibition-related hypertension

Area of Science:

• Oncology
• Cardiovascular Pharmacology

Background:

• Anti-angiogenesis therapies targeting vascular endothelial growth factor (VEGF) are standard for solid tumors.
• A frequent adverse event is treatment-induced hypertension, linked to reduced nitric oxide, endothelin pathway activation, and renin suppression.

Purpose of the Study:

• To investigate the mechanisms behind endothelin-signaling pathway activation during VEGF-targeted therapy.
• To explore the potential role of endothelial cell activation and disinhibition of VEGF-mediated endothelin suppression.

Main Methods:

• This study focuses on the mechanistic understanding of hypertension in patients undergoing anti-angiogenesis therapy.
• Investigates the interplay between VEGF signaling, endothelin pathways, and endothelial cell function.

Main Results:

• Hypertension in patients receiving VEGF inhibitors is associated with decreased nitric oxide and renin suppression.
• The precise mechanisms activating the endothelin-signaling pathway remain under investigation, with potential roles for endothelial cell activation and disinhibition of VEGF's suppressive effects.

Conclusions:

• Understanding the mechanisms of VEGF inhibitor-induced hypertension is crucial for managing side effects and optimizing cancer treatment.
• Hypertension development during anti-angiogenesis therapy might serve as a predictive biomarker for treatment efficacy.